Insider · CIK 0001666963
Winston Kung
cfoofficerdirector
Files at CRBP (Corbus Pharmaceuticals Holdings, Inc.), JANX (Janux Therapeutics, Inc.), AVBP (ArriVent BioPharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +3,750 | $0.00 | $0 | 6,250 | Jun 13, 2025 |
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,667 | $0.00 | $0 | 11,667 | Jun 13, 2025 |
| May 30, 2025 | CRBP Corbus Pharmaceuticals Holdings, Inc. | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 10,366 | Jun 2, 2025 |
| May 30, 2025 | CRBP Corbus Pharmaceuticals Holdings, Inc. | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| Feb 3, 2025 | AVBP ArriVent BioPharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 14, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.